[Translation] A single-center, open-label, randomized, single-dose, two-period, two-sequence, crossover bioequivalence trial evaluating the investigational formulation merogabarine besylate tablets (5 mg) and the reference formulation merogabarine besylate tablets (Delijin®, 5 mg) in healthy adult participants under fasting and postprandial conditions.
主要研究目的:研究空腹和餐后状态下单次口服受试制剂苯磺酸美洛加巴林片(规格:5 mg(按C12H19NO2计),福建东瑞制药有限公司生产)与参比制剂苯磺酸美洛加巴林片(德力静®,规格:5 mg(按C12H19NO2计),TAIYO Pharma Tech CO., LTD., Takatsuki Plant生产)在健康成年参与者体内的药代动力学特征,评价空腹和餐后状态口服两种制剂的生物等效性。
次要研究目的:研究受试制剂苯磺酸美洛加巴林片(规格:5 mg(按C12H19NO2计))和参比制剂苯磺酸美洛加巴林片(德力静®,规格:5 mg(按C12H19NO2计))在健康成年参与者中的安全性。
[Translation] Primary objective: To investigate the pharmacokinetic characteristics of a single oral dose of the test formulation merogabarine besylate tablets (5 mg (C12H19NO2), manufactured by Fujian Dongrui Pharmaceutical Co., Ltd.) and the reference formulation merogabarine besylate tablets (Delijing®, 5 mg (C12H19NO2), manufactured by TAIYO Pharma Tech CO., LTD., Takatsuki Plant) in healthy adult participants under fasting and postprandial conditions, and to evaluate the bioequivalence of the two formulations under fasting and postprandial conditions.
Secondary objective: To investigate the safety of the test formulation merogabarine besylate tablets (5 mg (C12H19NO2)) and the reference formulation merogabarine besylate tablets (Delijing®, 5 mg (C12H19NO2)) in healthy adult participants.